CCL27 and myeloid sarcoma: In comparison with non‐MS controls, MS patients prior to alemtuzumab onset demonstrated significantly lower ILC1, but higher ILC2 proportions among helper ILC (Figure 4a, ILC1, P = 0.0096; ILC2, P = 0.0168), which were not apparent postalemtuzumab treatment (Figure 4a).